N

Nippon Shinyaku Co Ltd
TSE:4516

Watchlist Manager
Nippon Shinyaku Co Ltd
TSE:4516
Watchlist
Price: 3 982 JPY 3.46% Market Closed
Market Cap: 268.3B JPY
Have any thoughts about
Nippon Shinyaku Co Ltd?
Write Note

Nippon Shinyaku Co Ltd
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Nippon Shinyaku Co Ltd
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
N
Nippon Shinyaku Co Ltd
TSE:4516
Income from Continuing Operations
ÂĄ26.1B
CAGR 3-Years
-15%
CAGR 5-Years
7%
CAGR 10-Years
18%
Takeda Pharmaceutical Co Ltd
TSE:4502
Income from Continuing Operations
ÂĄ290.2B
CAGR 3-Years
-15%
CAGR 5-Years
28%
CAGR 10-Years
12%
Daiichi Sankyo Co Ltd
TSE:4568
Income from Continuing Operations
ÂĄ250.7B
CAGR 3-Years
42%
CAGR 5-Years
17%
CAGR 10-Years
14%
Otsuka Holdings Co Ltd
TSE:4578
Income from Continuing Operations
ÂĄ155.2B
CAGR 3-Years
1%
CAGR 5-Years
5%
CAGR 10-Years
-1%
Chugai Pharmaceutical Co Ltd
TSE:4519
Income from Continuing Operations
ÂĄ387B
CAGR 3-Years
15%
CAGR 5-Years
23%
CAGR 10-Years
22%
Astellas Pharma Inc
TSE:4503
Income from Continuing Operations
ÂĄ54.7B
CAGR 3-Years
-23%
CAGR 5-Years
-26%
CAGR 10-Years
-7%
No Stocks Found

Nippon Shinyaku Co Ltd
Glance View

Market Cap
268.3B JPY
Industry
Pharmaceuticals

Nippon Shinyaku Co., Ltd. stands as a beacon in the Japanese pharmaceutical landscape, weaving a story that begins over a century ago. Originally founded to address the medical needs of its society, the company has strategically evolved its focus, channeling its expertise into two main business domains: pharmaceuticals and functional food. As it carved its niche, Nippon Shinyaku harnessed the power of innovation and research to develop drugs that address critical medical needs, especially in oncology, hematology, and rare diseases. This specialization not only strengthens its foothold but also embodies a moral commitment to enhancing patient quality of life, proving profitable as these fields often present less competition but promise high demand and returns. Alongside its pharmaceutical ventures, Nippon Shinyaku has leveraged the burgeoning wellness trend through its functional food segment, offering products that promote health and prevent disease. This dual approach leverages the company's bioscience expertise and diversifies its revenue streams, shielding it from the volatility often seen in the pharmaceutical sector. By making strategic alliances and collaborations, both domestically and overseas, Nippon Shinyaku accelerates its market penetration and expands its international footprint. As it capitalizes on its robust R&D capabilities, the company anchors its success on a fusion of scientific advancement and strategic acumen, crafting a narrative of resilience and adaptability in a rapidly evolving industry.

Intrinsic Value
4 781.58 JPY
Undervaluation 17%
Intrinsic Value
Price
N

See Also

What is Nippon Shinyaku Co Ltd's Income from Continuing Operations?
Income from Continuing Operations
26.1B JPY

Based on the financial report for Sep 30, 2024, Nippon Shinyaku Co Ltd's Income from Continuing Operations amounts to 26.1B JPY.

What is Nippon Shinyaku Co Ltd's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
18%

Over the last year, the Income from Continuing Operations growth was 10%. The average annual Income from Continuing Operations growth rates for Nippon Shinyaku Co Ltd have been -15% over the past three years , 7% over the past five years , and 18% over the past ten years .

Back to Top